Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

In this systematic review, ten studies reported risk reclassification of prostate cancer with genome classifier testing, with ...

With the publication of the long-term results of two randomized screening trials and updates to screening guidelines from many organizations, the past 2 years have been eventful in the field of ...

The top 10 companies in America’s Favorite Chains reflect this high-brow-low-brow contrast with snack-focused brands like ...

"Saw 2 frolicking in empty lot along Gleason (near Surfside ... so more localized studies would be needed to clarify hybridization patterns within the state. While hybridization is less documented ...

We've seen Bruce and Damian Wayne go through this dance time and time again, and it's just a tired and worn out Batman and ...

CYCLONE 2 was a seamless phase 2/3 adaptive trial with a dose-finding ... at least 50% of any one core involved, or Gleason pattern 4 or higher). The trial design for the MAST trial is as follows: ...